PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+15.91%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.19M
(+2.9%)
Cap. Flow
-$26.1M
Cap. Flow
% of AUM
-12.07%
Top 10 Holdings %
Top 10 Hldgs %
57.5%
Holding
62
New
15
Increased
10
Reduced
17
Closed
20
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$7.7M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$6.63M |
| 3 |
Prothena Corp
PRTA
|
+$6.46M |
| 4 |
Organogenesis Holdings
ORGO
|
+$6.4M |
| 5 |
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$4.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$13.5M |
| 2 |
uniQure
QURE
|
+$4.96M |
| 3 |
Centene
CNC
|
+$4.95M |
| 4 |
AC Immune
ACIU
|
+$4.66M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$3.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.72% |
| 2 | Miscellaneous | 8.38% |
| 3 | Technology | 3.62% |
| 4 | Energy | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
DELISTED
Kezar Life Sciences
KZR
| – | – |
-36,598
| Closed | -$1.77M | – |
|
52
Neurogene
NGNE
$444M
| – | – |
-3,319
| Closed | -$797K | – |
|
53
PUT
iShares S&P 100 ETF
OEF
$20.6B
| – | – |
-24,000
| Closed | -$3.6M | – |
|
54
QuidelOrtho
QDEL
$951M
| – | – |
-7,500
| Closed | -$1.65M | – |
|
55
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-15,826
| Closed | -$1.22M | – |
|
|
RETA
56
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-1,600
| Closed | -$156K | – |
|
|
APEN
57
DELISTED
Apollo Endosurgery, Inc.
APEN
| – | – |
-277,590
| Closed | -$469K | – |
|
|
ONEM
58
DELISTED
1Life Healthcare
ONEM
| – | – |
-65,778
| Closed | -$1.86M | – |
|
|
MITO
59
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
| – | – |
-256,044
| Closed | -$346K | – |
|
|
EVFM
60
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| – | – |
-16,667
| Closed | -$590K | – |
|
61
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| – | – |
-282,100
| Closed | -$3.84M | – |
|
62
DELISTED
BioTelemetry, Inc.
BEAT
| – | – |
-6,000
| Closed | -$274K | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2020 Portfolio in Review
As of Q4 2020, Prosight Management held 62 positions worth $216M, up 2.9% from $210M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Prosight Management withdrew a net $26.1M in Q4 2020, closing 20 positions and reducing 17 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $3.97M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Prosight Management opened a new position in Vertex Pharmaceuticals worth $6.83M.
- Prosight Management's largest Q4 2020 buy was Vertex Pharmaceuticals: 28,900 shares worth $6.83M.
- Prosight Management added most to Alexion Pharmaceuticals in Q4 2020, an estimated $7.7M increase.
- Prosight Management's biggest Q4 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $13.5M.
- Prosight Management fully exited Iovance Biotherapeutics in Q4 2020, selling an estimated $3.97M.
- Prosight Management's ten largest holdings make up 57% of its $216M portfolio in Q4 2020.
- Prosight Management opened 15 new positions and closed 20 in Q4 2020.
- Prosight Management's portfolio value rose 2.9% quarter-over-quarter to $216M.
Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.